Bertram Pitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoAnn arborNoord hollandCraig granowitzMarc bonacaBertram pittMichaelj daviesSchool of medicineCigna group evernorthLexicon pharmaceuticals inc selected financial dataEuropean society of cardiologyAlina kolomeyerlexicon pharmaceuticals incLexicon pharmaceuticals incInternational congress on neuropathic painLexicon investor relationslexicon pharmaceuticals inc

Review of the European Society of Cardiology (ESC) Congress 2023

The European Society of Cardiology (ESC) inaugural session unfolded against the backdrop of Amsterdam, the Netherlands.

South koreaNewcastle upon tyneUnited kingdomNoord hollandCity ofAnn arborUnited statesVastra frolundaVastra gotalands lanKyongsang namdoAnna meta kristensenGunnar olsonKyehwan kimMultivariable coxMengya liChris plummer

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

THE WOODLANDS, Texas, Aug. 21, 2023 Lexicon Pharmaceuticals, Inc. today announced that analyses of clinical study results relating to INPEFA™ , its recently approved drug for heart.

United statesAnn arborNoord hollandCarrie siragusaMarc bonacaAlina cocuzzaBertram pittLexicon pharmaceuticals incUniversity of colorado anschutz medical campusAmerican heart associationLexicon pharmaceuticalsExchange commissionAmsterdam convention centerDrug administrationGlobenewswire incUniversity of michigan

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug

United statesNoord hollandAnn arborBertram pittCarrie siragusaMarc bonacaAlina cocuzzaDrug administrationLexicon pharmaceuticals incLexicon pharmaceuticalsExchange commissionAmsterdam convention centerUniversity of michiganUniversity of colorado anschutz medical campusSchool of medicineConvention center

Post-hoc Findings From Inpefa Trial Show Benefit of Starting Drug Before Discharge

Results show that the new heart failure drug reduces the hospitalizations and risk of death from cardiovascular events.

United statesBertram pittBetram pittUniversity of michigan school medicineCardiovascular eventsPatients with typePost worsening heart failureMichigan schoolHeart failure